MCID: FTT008
MIFTS: 25

Fatty Liver Disease, Nonalcoholic 1

Categories: Liver diseases

Aliases & Classifications for Fatty Liver Disease, Nonalcoholic 1

MalaCards integrated aliases for Fatty Liver Disease, Nonalcoholic 1:

Name: Fatty Liver Disease, Nonalcoholic 1 53 28
Fatty Liver Disease, Nonalcoholic, Susceptibility to, 1 53 13
Hepatic Steatosis 71 28
Nafld1 53 71
Non-Alcoholic Fatty Liver Disease 1 71
Steatohepatitis 69
Fatty Liver 69

Characteristics:

OMIM:

53
Inheritance:
multifactorial

Miscellaneous:
genetic heterogeneity


HPO:

31
fatty liver disease, nonalcoholic 1:
Inheritance heterogeneous


Classifications:



External Ids:

OMIM 53 613282
MeSH 41 D005234
SNOMED-CT via HPO 65 197321007 442191002
UMLS 69 C2711227

Summaries for Fatty Liver Disease, Nonalcoholic 1

OMIM : 53 The accumulation of excess triglyceride in the liver, a condition known as hepatic steatosis (or fatty liver), is associated with adverse metabolic consequences including insulin resistance and dyslipidemia. Factors promoting deposition of fat in the liver include obesity, diabetes, insulin resistance, and alcohol ingestion. Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries. In a subset of individuals hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer (summary by Romeo et al., 2008). Cohen et al. (2011) reviewed nonalcoholic fatty liver disease. (613282)

MalaCards based summary : Fatty Liver Disease, Nonalcoholic 1, also known as fatty liver disease, nonalcoholic, susceptibility to, 1, is related to lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules and hypobetalipoproteinemia, familial, 1, and has symptoms including hepatic steatosis An important gene associated with Fatty Liver Disease, Nonalcoholic 1 is NAFLD1 (Fatty Liver Disease 1, Susceptiblity To). Affiliated tissues include liver.

UniProtKB/Swiss-Prot : 71 Non-alcoholic fatty liver disease 1: A condition characterized by accumulation of triglycerides in the liver. It is associated with adverse metabolic consequences, including insulin resistance and dyslipidemia. In a subset of individuals, hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer. NAFLD is the most common form of liver disease in Western countries.

Related Diseases for Fatty Liver Disease, Nonalcoholic 1

Diseases in the Fatty Liver Disease, Nonalcoholic 1 family:

Fatty Liver Disease, Nonalcoholic 2

Diseases related to Fatty Liver Disease, Nonalcoholic 1 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.1
2 hypobetalipoproteinemia, familial, 1 11.5
3 nonalcoholic steatohepatitis 10.9

Symptoms & Phenotypes for Fatty Liver Disease, Nonalcoholic 1

Symptoms via clinical synopsis from OMIM:

53
AbdomenLiver:
fatty liver (hepatic steatosis), nonalcoholic


Clinical features from OMIM:

613282

Human phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

31
# Description HPO Frequency HPO Source Accession
1 hepatic steatosis 31 HP:0001397

Drugs & Therapeutics for Fatty Liver Disease, Nonalcoholic 1

Search Clinical Trials , NIH Clinical Center for Fatty Liver Disease, Nonalcoholic 1

Genetic Tests for Fatty Liver Disease, Nonalcoholic 1

Genetic tests related to Fatty Liver Disease, Nonalcoholic 1:

# Genetic test Affiliating Genes
1 Fatty Liver Disease, Nonalcoholic 1 28
2 Hepatic Steatosis 28

Anatomical Context for Fatty Liver Disease, Nonalcoholic 1

MalaCards organs/tissues related to Fatty Liver Disease, Nonalcoholic 1:

38
Liver

Publications for Fatty Liver Disease, Nonalcoholic 1

Articles related to Fatty Liver Disease, Nonalcoholic 1:

(show top 50) (show all 241)
# Title Authors Year
1
Physical activity and Mediterranean diet based on olive tree phenolic compounds from two different geographical areas have protective effects on early osteoarthritis, muscle atrophy and hepatic steatosis. ( 29450729 )
2018
2
Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. ( 28797039 )
2017
3
Omega-3 PUFA ameliorates hyperhomocysteinemia-induced hepatic steatosis in mice by inhibiting hepatic ceramide synthesis. ( 28933423 )
2017
4
Protective effects of gomisin N against hepatic steatosis through AMPK activation. ( 27914812 )
2017
5
Human leucine zipper protein promotes hepatic steatosis via induction of apolipoprotein A-IV. ( 28246167 )
2017
6
Genetic variation in the microsomal triglyceride transfer protein (-493G/T) is associated with hepatic steatosis in patients infected with hepatitis C virus. ( 28356060 )
2017
7
Biochemical mechanism underlying hypertriglyceridemia and hepatic steatosis/hepatomegaly induced by acute schisandrin B treatment in mice. ( 28086886 )
2017
8
USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity. ( 28718215 )
2017
9
Activation of intestinal hypoxia-inducible factor 2I+ during obesity contributes to hepatic steatosis. ( 29035368 )
2017
10
Human hepatic lipase overexpression in mice induces hepatic steatosis and obesity through promoting hepatic lipogenesis and white adipose tissue lipolysis and fatty acid uptake. ( 29244870 )
2017
11
Inverse Relationship between Hepatic Steatosis and Alanine Aminotransferase with Sex Hormone-Binding Globulin in Men. ( 28540984 )
2017
12
Hepatic Steatosis Accompanies Pulmonary Alveolar Proteinosis. ( 28489415 )
2017
13
Transmembrane-6 superfamily member 2 (TM6SF2) E167K variant increases susceptibility to hepatic steatosis in obese children. ( 26520056 )
2016
14
PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis. ( 26419236 )
2016
15
Is there an influence of hepatic steatosis on fibrosis and necroinflammation in young patients with chronic viral hepatitis B? ( 27499150 )
2016
16
TFE3 Alleviates Hepatic Steatosis through Autophagy-Induced Lipophagy and PGC1I+-Mediated Fatty Acid I^-Oxidation. ( 26999124 )
2016
17
Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis activates Akt signaling to ameliorate hepatic steatosis. ( 26883384 )
2016
18
Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling: implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis. ( 27582413 )
2016
19
Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis. ( 26869449 )
2016
20
APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases. ( 27059980 )
2016
21
E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis. ( 26619117 )
2016
22
Long noncoding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability. ( 26935028 )
2016
23
Mesenteric Fat Lipolysis Mediates Obesity-Associated Hepatic Steatosis and Insulin Resistance. ( 26384383 )
2016
24
Loss of CTRP5 improves insulin action and hepatic steatosis. ( 27143553 )
2016
25
Soy isoflavones (Glycine max) ameliorate hypertriglyceridemia and hepatic steatosis in high fat-fed ovariectomized Wistar rats (an experimental model of postmenopausal obesity). ( 27723468 )
2016
26
Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein. ( 26637457 )
2016
27
N-Acetyl-L-Cysteine inhibits the development of glucose intolerance and hepatic steatosis in diabetes-prone mice. ( 27725855 )
2016
28
PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. ( 26355465 )
2016
29
Hyperhomocysteinemia Activates the Aryl Hydrocarbon Receptor-CD36 Pathway to Promote Hepatic Steatosis in Mice. ( 26928949 )
2016
30
Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity. ( 27660157 )
2016
31
Usefulness of Magnetic Resonance Imaging for the Diagnosis of Hemochromatosis with Severe Hepatic Steatosis in Nonalcoholic Fatty Liver Disease. ( 27580542 )
2016
32
Hepatic steatosis depresses alpha-1-antitrypsin levels in human and rat acute pancreatitis. ( 26634430 )
2015
33
The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. ( 26599080 )
2015
34
Tissue Inhibitor Of Matrix Metalloproteinase-1 Is Required for High-Fat Diet-Induced Glucose Intolerance and Hepatic Steatosis in Mice. ( 26168159 )
2015
35
Effect of Creosote Bush-Derived NDGA on Expression of Genes Involved in Lipid Metabolism in Liver of High-Fructose Fed Rats: Relevance to NDGA Amelioration of Hypertriglyceridemia and Hepatic Steatosis. ( 26394137 )
2015
36
Oleic acid-induced hepatic steatosis is coupled with downregulation of aquaporin 3 and upregulation of aquaporin 9 via activation of p38 signaling. ( 25105540 )
2015
37
Expression of seipin in adipose tissue rescues lipodystrophy, hepatic steatosis and insulin resistance in seipin null mice. ( 25757906 )
2015
38
Hepatic steatosis in Wilson disease - role of copper and PNPLA3 mutations. ( 25678388 )
2015
39
FOCAL HEPATIC STEATOSIS AROUND MALIGNANT INSULINOMA. ( 26523629 )
2015
40
Apolipoprotein D Transgenic Mice Develop Hepatic Steatosis through Activation of PPARI^ and Fatty Acid Uptake. ( 26083030 )
2015
41
Naringenin prevents obesity, hepatic steatosis and glucose intolerance in male mice independent of Fibroblast Growth Factor 21. ( 25774553 )
2015
42
Hepatic lipase deficiency produces glucose intolerance, inflammation and hepatic steatosis. ( 26423094 )
2015
43
C1q/TNF-Related Protein 9 (CTRP9) attenuates hepatic steatosis via the autophagy-mediated inhibition of endoplasmic reticulum stress. ( 26419929 )
2015
44
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. ( 24917523 )
2015
45
Automated two-point dixon screening for the evaluation of hepatic steatosis and siderosis: comparison with R2*-relaxometry and chemical shift-based sequences. ( 25501270 )
2015
46
Curcumin attenuates ethanol-induced hepatic steatosis through modulating Nrf2/FXR signaling in hepatocytes. ( 26305715 )
2015
47
PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. ( 26139292 )
2015
48
Effect of PNPLA3 rs738409 variant (I148 M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C. ( 25543233 )
2015
49
Mitochondrial aldehyde dehydrogenase activation by alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein e-knockout mice. ( 25392542 )
2014
50
Highly expressed MT-ND3 positively associated with histological severity of hepatic steatosis. ( 24020820 )
2014

Variations for Fatty Liver Disease, Nonalcoholic 1

Expression for Fatty Liver Disease, Nonalcoholic 1

Search GEO for disease gene expression data for Fatty Liver Disease, Nonalcoholic 1.

Pathways for Fatty Liver Disease, Nonalcoholic 1

GO Terms for Fatty Liver Disease, Nonalcoholic 1

Sources for Fatty Liver Disease, Nonalcoholic 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....